NCT04438083View on ClinicalTrials.gov

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

PHASE1TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

CTX130

CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.

Trial Locations (7)

1066

Research Site 7, Amsterdam

3000

Research Site 1, Melbourne

77030

Research Site 4, Houston

84112

Research Site 3, Salt Lake City

91010

Research Site 2, Duarte

06520

Research Site 5, Hartford

M5G 2M9

Research Site 6, Toronto

Sponsors
All Listed Sponsors
lead

CRISPR Therapeutics AG

INDUSTRY